BridgeMD
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
EU CTIS ID: 2023-508207-21-00
What this study is testing
- Part 1A and Part 1B: To determine the safety, tolerability, DLTs, and MTD of relatlimab administered in combination with nivolumab and BMS-986205 or nivolumab and ipilimumab in participants with advanced malignant tumors. - Part 2A and Part 2B: To investigate safety and tolerability of relatlimab triple combinations in distinct cohorts of participants with advanced malignant tumors. - To investigate the antitumor activity of relatlimab triple combinations in participants with advanced malignant tumors.
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- - Histologic or cytologic confirmation of an incurable solid malignancy that is advanced (metastatic and/or unresectable), with measurable disease per RECIST v1.1
- -Available tumor tissue for biomarker analysis
- - Eastern Cooperative Oncology Group Performance Status (ECOG) status of 0 or 1
You likely can't join if
- - Participants with known or suspected uncontrolled CNS metastases or with the CNS as the only site of active disease
- - Participants with a history of interstitial lung disease (ILD) /pneumonitis
- - Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment assignment (ie, participants with a history of prior malignancy are eligible if treatment was completed at least 2 years before treatment assignment and the participant has no evidence of disease). Participants with history of prior early stage basal/squamous cell skin cancer or noninvasive or in situ cancers that have undergone definitive treatment at any time are also eligible
The study team makes the final eligibility decision.
Where it's taking place
- Australia
- Switzerland
- United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Australia; Switzerland; United Kingdom. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.